Showing 61 - 80 results of 113,959 for search '(( a web decrease ) OR ((( 12 we decrease ) OR ( 5 ((a decrease) OR (mean decrease)) ))))', query time: 1.39s Refine Results
  1. 61
  2. 62
  3. 63

    A Functional 12T-Insertion Polymorphism in the <i>ATP1A1</i> Promoter Confers Decreased Susceptibility to Hypertension in a Male Sardinian Population by Victoria L. Herrera (383897)

    Published 2015
    “…The <i>ATP1A1</i> promoter containing the 12T-insertion exhibited decreased transcriptional activity in in vitro reporter-assay systems, indicating decreased α1Na,K-ATPase expression with the 12T-insertion, compared with the 12T-deletion <i>ATP1A1</i> promoter. …”
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69

    Decreased innervation and decreased epidermal thickness in STZ diabetic rats. by Shoista Kambiz (740608)

    Published 2015
    “…<p>Decreased density PGP9.5-IR nerve fibers (<b>A</b>) and average epidermal thickness (<b>F</b>) was demonstrated in the plantar skin of diabetic animals 4, 6, and 8 weeks after induction of diabetes (black bars) when compared to control (white bar). …”
  10. 70
  11. 71

    Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization by figshare admin karger (2628495)

    Published 2025
    “…This study investigated clinical characteristics and outcomes associated with longitudinal decreases in LV size in this population. Methods: We analyzed echocardiographic data from 6,232 adults with normal baseline left ventricular end-diastolic diameter (LVEDD), with a mean interval of 4.8 years between baseline and follow-up echocardiograms. …”
  12. 72
  13. 73
  14. 74

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  15. 75

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  16. 76

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  17. 77

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  18. 78

    Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

    Published 2021
    “…<b><i>Introduction:</i></b> Prevention of attacks is a major goal in management of patients with hereditary angioedema (HAE). We aimed to investigate the effects of a systematic intervention for HAE patients. …”
  19. 79

    Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients by Anni A. Winckelmann (407551)

    Published 2013
    “…We observed a mean reduction in proviral DNA in the CPG group of 12.6% (95% CI: −23.6–0.0) following each immunization whereas proviral DNA in the placebo-adjuvant group remained largely unchanged (6.7% increase; 95% CI: −4.2–19.0 after each immunization, p = 0.02). …”
  20. 80